$FDMT News

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular Degeneration

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Transcript

4DMT to Participate in Upcoming Investor Conferences

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones

4D Molecular Therapeutics Files Prospectus To Offer And Sell Up To $400M Of Securities In Multiple Offerings

4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35